Examkin

Soru

Zorluk: ZorNormal Pregnancy and Prenatal Care

A 27-year-old primigravida presents for her initial prenatal visit at 8 weeks gestation. Her blood type is subsequently confirmed to be O, Rh(D)-negative. She experiences an uncomplicated pregnancy and delivers a healthy, Rh(D)-positive infant at 39 weeks gestation. A routine postpartum screening test indicates the presence of a significant fetomaternal hemorrhage. Arrange the following clinical steps regarding her Rh(D) management in the standard chronological sequence required to evaluate and prevent maternal alloimmunization, from the first trimester through her postpartum care.

  1. 1Performance of a baseline maternal atypical antibody screen
  2. 2Performance of a repeat maternal atypical antibody screen
  3. 3Administration of routine antenatal prophylactic anti-D immune globulin
  4. 4Performance of a maternal erythrocyte rosette test
  5. 5Performance of a Kleihauer-Betke test to calculate the targeted postpartum anti-D immune globulin dose

Cevap

The correct chronological sequence is: Baseline antibody screen, Repeat antibody screen at 28 weeks, Antenatal anti-D immune globulin administration, Postpartum rosette test, and finally Postpartum Kleihauer-Betke test.
The prevention of Rh(D) alloimmunization follows a strict chronological protocol. The sequence begins with a baseline atypical antibody screen at the initial prenatal visit to rule out prior sensitization. At 28 weeks, a repeat antibody screen must be drawn to confirm the patient is still not sensitized. Immediately following this negative screen, standard antenatal prophylaxis (300 mcg of anti-D immune globulin) is given. Postpartum, after confirming the infant is Rh(D)-positive, maternal blood is screened qualitatively using the rosette test to detect significant fetomaternal hemorrhage. If the rosette test is positive, the Kleihauer-Betke test (or flow cytometry) is used to quantify the volume of fetal red blood cells in the maternal circulation. This allows the physician to calculate and administer the appropriate customized dose of postpartum anti-D immune globulin (typically 300 mcg for every 30 mL of fetal whole blood).

Adım Adım Çözüm

1
Identify the patient's baseline risk at the initial prenatal visit.
Because she is Rh(D)-negative, a baseline atypical antibody screen is drawn.
This establishes whether she is already alloimmunized; if positive, prophylactic immune globulin is contraindicated and the pregnancy requires high-risk maternal-fetal medicine management.
2
Determine the necessary testing at the beginning of the third trimester (28 weeks).
A repeat atypical antibody screen is performed.
This verifies that silent sensitization has not occurred during the first two trimesters, which must be confirmed before exogenous antibodies are administered.
3
Administer standard third-trimester prophylaxis.
Routine 300 mcg of anti-D immune globulin is given at 28 weeks.
This provides passive immunity during the third trimester, when the risk of minor fetomaternal hemorrhage increases.
4
Assess fetomaternal hemorrhage risk immediately postpartum.
Because the infant is confirmed to be Rh(D)-positive, a qualitative rosette test is performed on maternal blood.
This screens for the presence of a fetomaternal hemorrhage greater than 30 mL of whole fetal blood, which would exceed the coverage of a single standard 300 mcg dose of immune globulin.
5
Quantify the hemorrhage to finalize the postpartum treatment dose.
Following the positive rosette test, a Kleihauer-Betke test is performed.
This accurately calculates the exact volume of fetal blood in the maternal circulation, allowing the physician to administer the appropriate weight-based postpartum dose of anti-D immune globulin within 72 hours of delivery.

Anahtar Kavram

Rh(D) Alloimmunization Prevention Pathway
Bu soruyu puanla

Konular

Normal Pregnancy and Prenatal Care

Bu konudan daha fazla soru